A Phase 1 interventional study of BI 1291583 and [14C]-BI 1291583 in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main objective of this trial is to investigate the absolute bioavailability of BI 1291583 (test treatment T, not radio-labelled) compared with BI 1291583 (C-14) (reference treatment R).
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BI 1291583 · Drug: [14C]-BI 1291583
Drug: BI 1291583 · Drug: [14C]-BI 1291583
BI 1291583
Also known as: Verducatib
\[14C\]-BI 1291583
Also known as: Verducatib
Area Under the Concentration-time Curve of BI 1291583/[14C]-BI 1291583 Over the Time Interval From 0 Extrapolated to Infinity - Dose Normalized
This outcome measured the area under the concentration-time curve over the time interval from 0 extrapolated to infinity (AUC0-∞) of intravenous (i.v.) \[14C\]-BI 1291583 and of BI 1291583 1 milligrams (mg) or 5 mg after oral administration. The AUC0-∞ is presented normalized by the dose administered. The statistical model was an analysis of variance (ANOVA) including 'treatment' as a fixed effect and 'subject' as a random effect. The time frame for analysis of \[14C\]-BI 1291583 in the reference groups R1 and R5 was 9 hours before, immediately before and 0.08, 0.17, 0.25, 0.5, 2, 4, 6, 8, 18, 42, 66, 138 and 210 hours after i.v. administration. The time frame for analysis of BI 1291583 in the test groups T1 and T5 was 3 hours before and 1, 1.5, 2, 3, 4, 6, 6.5, 8, 10, 12, 14, 24, 48, 72, 144 and 216 hours after oral administration.
Time frame: Up to 219 hours. The detailed timeframe is in the outcome description.
Maximum Measured Concentration of BI 1291583/[14C]-BI 1291583 in Plasma (Cmax) - Dose Normalized
This outcome measured the maximum concentration in plasma (Cmax) of intravenous (i.v.) \[14C\]-BI 1291583 and of BI 1291583 1 milligrams (mg) or 5 mg after oral administration. The Cmax is presented normalized by the dose administered. The statistical model was an analysis of variance (ANOVA) including 'treatment' as a fixed effect and 'subject' as a random effect. The time frame for analysis of \[14C\]-BI 1291583 in the reference groups R1 and R5 was 9 hours before, immediately before and 0.08, 0.17, 0.25, 0.5, 2, 4, 6, 8, 18, 42, 66, 138 and 210 hours after i.v. administration. The time frame for analysis of BI 1291583 in the test groups T1 and T5 was 3 hours before and 1, 1.5, 2, 3, 4, 6, 6.5, 8, 10, 12, 14, 24, 48, 72, 144 and 216 hours after oral administration.
Time frame: Up to 219 hours. The detailed timeframe is in the outcome description.
Area Under the Concentration-time Curve of BI 1291583/[14C]-BI 1291583 in Plasma Over the Time Interval From 0 to the Last Quantifiable Time Point (AUC0-tz) - Dose Normalized
This outcome measured the area under the concentration-time curve in plasma over the time interval from 0 to the last quantifiable time point (AUC0-tz) of intravenous (i.v.) \[14C\]-BI 1291583 and of BI 1291583 1 milligrams (mg) or 5 mg after oral administration. The AUC0-tz is presented normalized by the dose administered. The statistical model was an analysis of variance (ANOVA) including 'treatment' as a fixed effect and 'subject' as a random effect. The time frame for analysis of \[14C\]-BI 1291583 in the reference groups R1 and R5 was 9 hours before, immediately before and 0.08, 0.17, 0.25, 0.5, 2, 4, 6, 8, 18, 42, 66, 138 and 210 hours after i.v. administration. The time frame for analysis of BI 1291583 in the test groups T1 and T5 was 3 hours before and 1, 1.5, 2, 3, 4, 6, 6.5, 8, 10, 12, 14, 24, 48, 72, 144 and 216 hours after oral administration.
Time frame: Up to 219 hours. The detailed timeframe is in the outcome description.
Non-randomised, open-label, 2-arm, single period trial in healthy male participants to investigate the absolute bioavailability of BI 1291583 administered as tablet (test treatment - T - not radio-labeled) compared with BI 1291583 (C-14) (reference treatment - R) administered as intravenous (i.v.) microtracer. Participants were assigned to one of 2 dose groups, either 1 mg or one 5 mg BI 1291583 tablet followed by the reference treatment.
| Milestone | 1 mg BI 1291583 Tablet (T1), Then 50 μg BI 1291583 (C-14) i.v. (R1) | 5 mg BI 1291583 Tablet (T5), Then 50 μg BI 1291583 (C-14) i.v. (R5) |
|---|---|---|
| Started | 7 | 7 |
| Completed | 7 | 7 |
| Not completed | 0 | 0 |
This outcome measured the area under the concentration-time curve over the time interval from 0 extrapolated to infinity (AUC0-∞) of intravenous (i.v.) \[14C\]-BI 1291583 and of BI 1291583 1 milligrams (mg) or 5 mg after oral administration. The AUC0-∞ is presented normalized by the dose administered. The statistical model was an analysis of variance (ANOVA) including 'treatment' as a fixed effect and 'subject' as a random effect. The time frame for analysis of \[14C\]-BI 1291583 in the reference groups R1 and R5 was 9 hours before, immediately before and 0.08, 0.17, 0.25, 0.5, 2, 4, 6, 8, 18, 42, 66, 138 and 210 hours after i.v. administration. The time frame for analysis of BI 1291583 in the test groups T1 and T5 was 3 hours before and 1, 1.5, 2, 3, 4, 6, 6.5, 8, 10, 12, 14, 24, 48, 72, 144 and 216 hours after oral administration.
| hour*millimole/liter/kilogram | 1 mg BI 1291583 Tablet - T1 | 50 μg BI 1291583 (C-14) i.v. - R1 | 5 mg BI 1291583 Tablet - T5 | 50 μg BI 1291583 (C-14) i.v. - R5 |
|---|---|---|---|---|
| Area Under the Concentration-time Curve of BI 1291583/[14C]-BI 1291583 Over the Time Interval From 0 Extrapolated to Infinity - Dose Normalized | 14.50 ± NA | 26.35 ± NA | 19.65 ± NA | 32.70 ± NA |
This outcome measured the maximum concentration in plasma (Cmax) of intravenous (i.v.) \[14C\]-BI 1291583 and of BI 1291583 1 milligrams (mg) or 5 mg after oral administration. The Cmax is presented normalized by the dose administered. The statistical model was an analysis of variance (ANOVA) including 'treatment' as a fixed effect and 'subject' as a random effect. The time frame for analysis of \[14C\]-BI 1291583 in the reference groups R1 and R5 was 9 hours before, immediately before and 0.08, 0.17, 0.25, 0.5, 2, 4, 6, 8, 18, 42, 66, 138 and 210 hours after i.v. administration. The time frame for analysis of BI 1291583 in the test groups T1 and T5 was 3 hours before and 1, 1.5, 2, 3, 4, 6, 6.5, 8, 10, 12, 14, 24, 48, 72, 144 and 216 hours after oral administration.
| picomole/liter/microgram | 1 mg BI 1291583 Tablet - T1 | 50 μg BI 1291583 (C-14) i.v. - R1 | 5 mg BI 1291583 Tablet - T5 | 50 μg BI 1291583 (C-14) i.v. - R5 |
|---|---|---|---|---|
| Maximum Measured Concentration of BI 1291583/[14C]-BI 1291583 in Plasma (Cmax) - Dose Normalized | 0.32 ± NA | 27.21 ± NA | 0.53 ± NA | 24.05 ± NA |
This outcome measured the area under the concentration-time curve in plasma over the time interval from 0 to the last quantifiable time point (AUC0-tz) of intravenous (i.v.) \[14C\]-BI 1291583 and of BI 1291583 1 milligrams (mg) or 5 mg after oral administration. The AUC0-tz is presented normalized by the dose administered. The statistical model was an analysis of variance (ANOVA) including 'treatment' as a fixed effect and 'subject' as a random effect. The time frame for analysis of \[14C\]-BI 1291583 in the reference groups R1 and R5 was 9 hours before, immediately before and 0.08, 0.17, 0.25, 0.5, 2, 4, 6, 8, 18, 42, 66, 138 and 210 hours after i.v. administration. The time frame for analysis of BI 1291583 in the test groups T1 and T5 was 3 hours before and 1, 1.5, 2, 3, 4, 6, 6.5, 8, 10, 12, 14, 24, 48, 72, 144 and 216 hours after oral administration.
| hour*millimole/liter/kilogram | 1 mg BI 1291583 Tablet - T1 | 50 μg BI 1291583 (C-14) i.v. - R1 | 5 mg BI 1291583 Tablet - T5 | 50 μg BI 1291583 (C-14) i.v. - R5 |
|---|---|---|---|---|
| Area Under the Concentration-time Curve of BI 1291583/[14C]-BI 1291583 in Plasma Over the Time Interval From 0 to the Last Quantifiable Time Point (AUC0-tz) - Dose Normalized | 9.12 ± NA | 17.53 ± NA | 18.57 ± NA | 30.66 ± NA |
Collected over All-cause mortality: From first drug administration to individual end of study. Up to day 14. Adverse event reporting: From first drug administration to last drug administration plus 10 days residual effect period. Up to 10 days and 6 hours.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1 mg BI 1291583 Tablet (T1), Then 50 μg BI 1291583 (C-14) i.v. (R1) | 0/7 (0%) | 0/7 (0%) | 3/7 (42.9%) |
| 5 mg BI 1291583 Tablet (T5), Then 50 μg BI 1291583 (C-14) i.v. (R5) | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Event | 1 mg BI 1291583 Tablet (T1), Then 50 μg BI 1291583 (C-14) i.v. (R1) | 5 mg BI 1291583 Tablet (T5), Then 50 μg BI 1291583 (C-14) i.v. (R5) |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/7 | 3/7 |
| Vessel puncture site haematomaGeneral disorders | 0/7 | 2/7 |
| Catheter site haematomaGeneral disorders | 0/7 | 1/7 |
| FatigueGeneral disorders | 1/7 | 0/7 |
| Infusion site haematomaGeneral disorders | 0/7 | 1/7 |
| Infusion site painGeneral disorders | 1/7 | 0/7 |
| NasopharyngitisInfections and infestations | 1/7 | 0/7 |
| ContusionInjury, poisoning and procedural complications | 1/7 | 0/7 |
| Back painMusculoskeletal and connective tissue disorders | 0/7 | 1/7 |
| Muscle twitchingMusculoskeletal and connective tissue disorders | 1/7 | 0/7 |
Treated set (TS) - all participants who were treated with at least one dose of trial drug.
| Age, Continuous(Years) | 1 mg BI 1291583 Tablet (T1), Then 50 μg BI 1291583 (C-14) i.v. (R1) | 5 mg BI 1291583 Tablet (T5), Then 50 μg BI 1291583 (C-14) i.v. (R5) | Total |
|---|---|---|---|
| Mean | 21.1 ± 1.6 | 25.7 ± 4.6 | 23.4 ± 4.1 |
| Sex: Female, Male(Participants) | 1 mg BI 1291583 Tablet (T1), Then 50 μg BI 1291583 (C-14) i.v. (R1) | 5 mg BI 1291583 Tablet (T5), Then 50 μg BI 1291583 (C-14) i.v. (R5) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 7 | 7 | 14 |
| Ethnicity (NIH/OMB)(Participants) | 1 mg BI 1291583 Tablet (T1), Then 50 μg BI 1291583 (C-14) i.v. (R1) | 5 mg BI 1291583 Tablet (T5), Then 50 μg BI 1291583 (C-14) i.v. (R5) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 7 | 7 | 14 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 1 mg BI 1291583 Tablet (T1), Then 50 μg BI 1291583 (C-14) i.v. (R1) | 5 mg BI 1291583 Tablet (T5), Then 50 μg BI 1291583 (C-14) i.v. (R5) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 7 | 6 | 13 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Dec 2023 to primary completion in Feb 2024, 1 month.
Results were first posted in Nov 2026, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Verducatib